Year: 2021
Type: editorial
Abstract: For a long time, until the programmes started managing drugs resistant TB patients, the National Tuberculosis Control programmes were implemented for achieving good success rates for the patients infected with drug susceptible bacteria so that we are able to minimize the development of drug resistant strains.In addition, the programmes have been implemented on the premise that the drug resistance develops in two ways: Primary Drug Resistance or Acquired Drug Resistance.The main reasons for the acquired drug resistance being patient related issues like compliance or adherence, systemic issues like inadequate drug regimen or monotherapy, issue related to quality or supply of drugs or social issue like myths on the intake of Anti-TB drugs etc.Primary Drug resistance means the patient is infected with bacteria which are already resistant to drugs.The National Programmes adopted DOTS strategy which was expected to address the issues related to compliance, regimen or uninterrupted supply of good quality drugs.However, so far, the programmes have not been acknowledging or addressing issues other than conventionally thought causes for development of drug resistance.Effective first line treatment was expected to prevent emergence of drug resistance a s a public health measure.But the data suggest that primary transmission of drug resistant strains is now driving the spread of resistance including the high TB burden countries.It means the traditionally believed causes of development of drug resistance have now taken a back seat and the new emerging data indicates many other causes of development of drug resistance.
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4327509589